We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

77 hedge funds and large institutions have $159M invested in Alaunos Therapeutics in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

91% more capital invested

Capital invested by funds: $83.2M → $159M (+$75.7M)

10% more funds holding

Funds holding: 7077 (+7)

9% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $3.88M

5% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
77
Holders Change
+7
Holders Change %
+10%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
14
Increased
22
Reduced
21
Closed
6
Calls
$4.24M
Puts
$3.88M
Net Calls
+$362K
Net Calls Change
-$953K

TCRT Hedge Fund Activity: Q3 2013 in Review

77 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2013, worth a combined $159M — up 91% from $83.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new TCRT positions and 6 closed out — a net gain of 8 holders — while 22 added to existing stakes and 21 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $2.35M. The largest seller was SAC Capital Advisors, exiting entirely with an estimated $1.86M sold.

  • 77 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2013, up from 70 in Q2 2013.
  • Funds reported $159M of Alaunos Therapeutics stock for Q3 2013, up 91% quarter-over-quarter.
  • 14 funds opened new Alaunos Therapeutics positions in Q3 2013 and 6 closed out, a net change of +8 holders.
  • The largest Alaunos Therapeutics buyer in Q3 2013 was Jennison Associates, an estimated $2.35M added.
  • The largest Alaunos Therapeutics seller in Q3 2013 was SAC Capital Advisors, an estimated $1.86M sold.

Based on aggregated 13F filings for Q3 2013.